238 related articles for article (PubMed ID: 30304722)
1. Comparison between Hyper-CVAD and PETHEMA ALL-93 in Adult Acute Lymphoblastic Leukemia: A Single-Center Study.
Erkut N; Akidan O; Selim Batur D; Karabacak V; Sonmez M
Chemotherapy; 2018; 63(4):207-213. PubMed ID: 30304722
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of chemotherapy protocols for hematological malignancies: H-CVAD versus GELA/BURKIMAB/PETHEMA LAL.
Marín-Sánchez A; Martínez-Fernández G; Gómez-Catalán I; Montoya-Morcillo MC; Algarra-Algarra JL; Ibañez-García Á; Hernández-Fernández F; Romero-Macías JR
Exp Hematol; 2021 Sep; 101-102():49-57. PubMed ID: 34403757
[TBL] [Abstract][Full Text] [Related]
3. Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis.
El-Cheikh J; El Dika I; Massoud R; Charafeddine M; Mahfouz R; Kharfan-Dabaja MA; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):179-185. PubMed ID: 27988194
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
[TBL] [Abstract][Full Text] [Related]
5. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM
Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284
[TBL] [Abstract][Full Text] [Related]
6. The Dana Farber consortium protocol (DFCP) vs. classic Hyper-CVAD for treatment of acute lymphoblastic leukemia in patients <50 Y. Single institution experience.
Alabdulwahab AS; Elsayed HG; Sherisher MA; Zeeneldin A; Alghamdi K; Elbjeirami WM
Leuk Res; 2017 Sep; 60():58-62. PubMed ID: 28704720
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of modified hyper-CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience.
Jalaeikhoo H; Rajaeinejad M; Keyhani M; Zokaasadi M; Dehghani Firoozabadi MM
Cancer Med; 2018 Mar; 7(3):594-599. PubMed ID: 29383863
[TBL] [Abstract][Full Text] [Related]
8. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen.
Rytting ME; Jabbour EJ; Jorgensen JL; Ravandi F; Franklin AR; Kadia TM; Pemmaraju N; Daver NG; Ferrajoli A; Garcia-Manero G; Konopleva MY; Borthakur G; Garris R; Wang S; Pierce S; Schroeder K; Kornblau SM; Thomas DA; Cortes JE; O'Brien SM; Kantarjian HM
Am J Hematol; 2016 Aug; 91(8):819-23. PubMed ID: 27178680
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and outcome of the hyper-CVAD regimen in patients with adult acute lymphoblastic leukemia.
Portugal RD; Loureiro MM; Garnica M; Pulcheri W; Nucci M
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):52-7. PubMed ID: 25037887
[TBL] [Abstract][Full Text] [Related]
10. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian HM; O'Brien S; Smith TL; Cortes J; Giles FJ; Beran M; Pierce S; Huh Y; Andreeff M; Koller C; Ha CS; Keating MJ; Murphy S; Freireich EJ
J Clin Oncol; 2000 Feb; 18(3):547-61. PubMed ID: 10653870
[TBL] [Abstract][Full Text] [Related]
11. Hyper-CVAD regimen in routine management of adult acute lymphoblastic leukemia: a retrospective multicenter study.
Buyukasik Y; Acar K; Kelkitli E; Uz B; Serefhanoglu S; Ozdemir E; Pamukcuoglu M; Atay H; Bektas O; Sucak GT; Turgut M; Aksu S; Yagci M; Sayınalp N; Ozcebe OI; Goker H; Haznedaroglu IC
Acta Haematol; 2013; 130(3):199-205. PubMed ID: 23797290
[TBL] [Abstract][Full Text] [Related]
12. Outcome of treatment with Hyper-CVAD regimen in Chinese patients with acute lymphocytic leukemia.
Xu W; Li JY; Qian SX; Wu HX; Lu H; Chen LJ; Zhang SJ; Lu RL; Sheng RL
Leuk Res; 2008 Jun; 32(6):930-5. PubMed ID: 18061665
[TBL] [Abstract][Full Text] [Related]
13. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.
O'Brien S; Thomas DA; Ravandi F; Faderl S; Pierce S; Kantarjian H
Cancer; 2008 Oct; 113(8):2097-101. PubMed ID: 18720356
[TBL] [Abstract][Full Text] [Related]
14. Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults.
Guzauskas GF; Villa KF; Vanhove GF; Fisher VL; Veenstra DL
J Adolesc Young Adult Oncol; 2017 Mar; 6(1):53-61. PubMed ID: 27779442
[TBL] [Abstract][Full Text] [Related]
15. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Faderl S; Kantarjian HM; Thomas DA; Cortes J; Giles F; Pierce S; Albitar M; Estrov Z
Leuk Lymphoma; 2000 Jan; 36(3-4):263-73. PubMed ID: 10674898
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of the Hyper-CVAD with an institutional regimen for the treatment of acute lymphoblastic leukemia in adults in a hospital of Mexico].
Ramos-Peñafiel CO; Cabrera-García Á; Rozen-Fuller E; González-León G; Balderas C; Kassack-Ipiña JJ; Castellanos-Sinco H; Martínez-Murillo C; Montaño-Figueroa E; Martínez-Tovar A; Olarte-Carrillo I; Santoyo-Sánchez A; Collazo-Jaloma J
Rev Peru Med Exp Salud Publica; 2014; 31(3):525-9. PubMed ID: 25418653
[TBL] [Abstract][Full Text] [Related]
17. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
Thomas DA; O'Brien S; Cortes J; Giles FJ; Faderl S; Verstovsek S; Ferrajoli A; Koller C; Beran M; Pierce S; Ha CS; Cabanillas F; Keating MJ; Kantarjian H
Blood; 2004 Sep; 104(6):1624-30. PubMed ID: 15178574
[TBL] [Abstract][Full Text] [Related]
18. Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers.
Alacacioglu I; Medeni SS; Ozsan GH; Payzin B; Sevindik OG; Acar C; Katgi A; Ozdemirkan F; Piskin O; Ozcan MA; Undar B; Demirkan F
Chemotherapy; 2014; 60(4):219-23. PubMed ID: 25871894
[TBL] [Abstract][Full Text] [Related]
19. [A clinical report on modified Hyper-CVAD regimen in patients with lymphoblastic lymphoma].
Shi W; Shi YK; He XH; Zhou SY; Dong M; Zhang CG; Yang JL; Liu P; Qin Y; Yang S; Gui L
Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(14):978-81. PubMed ID: 20646648
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
Weiser MA; O'Brien S; Thomas DA; Pierce SA; Lam TP; Kantarjian HM
Cancer; 2002 Jan; 94(2):285-91. PubMed ID: 11900213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
